Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer
Inclusion Criteria:
- Non-hematological malignancy that has progressed on standard therapy
- No more that 3 prior chemotherapies given for advanced cancer
- Adequate renal, hepatic and hematologic function
Exclusion Criteria:
- Uncontrolled or significant pulmonary or cardiovascular disease
- Active Brain metastases
- Inability to swallow capsules
- Serious uncontrolled medical disorder or active infection
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To assess the Pharmacokinetics, metabolism, and routes and extent of elimination of a single dose of [14C] BMS-275183 over a 10 day period.
Authority:
United States: Food and Drug Administration
Study ID:
CA165-017
NCT ID:
NCT00326131
Start Date:
April 2006
Completion Date:
Related Keywords:
- Cancer
Name | Location |
|---|---|
| Local Institution | Austin, Texas |
